Colorectal cancer (CRC) represents approximately 10% of all cancers and is the second
most common cause of cancer deaths. Initial clinical presentation as metastatic CRC …

Over the past two decades, elucidation of the genetic defects that underlie cancer has
resulted in a plethora of novel targeted cancer drugs. Although these agents can initially be …

The establishing of the first cancer models created a new perspective on the identification
and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft …

Recent rapid biotechnological breakthroughs have led to the identification of complex and
unique molecular features that drive malignancies. Precision medicine has exploited next …

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical
efficacy in BRAFV600E colorectal cancer (CRC), response rates remain low and lack …

Metastatic colorectal cancer (mCRC) remains a lethal disease with an approximately 14% 5-
year survival rate. While early-stage colorectal cancer (CRC) can be cured by surgery with …

PURPOSE BEACON CRC evaluated encorafenib plus cetuximab with or without binimetinib
versus investigators' choice of irinotecan or FOLFIRI plus cetuximab in patients with BRAF …

The identification of molecular targets and the growing knowledge of their cellular functions
have led to the development of small molecule inhibitors as a major therapeutic class for …

Anti-BRAF/EGFR therapy was recently approved for the treatment of metastatic BRAF V600E
colorectal cancer (mCRCBRAF-V600E). However, a large fraction of patients do not …

The first wave of genetically targeted therapies for cancer focused on drugging gene
products that are recurrently mutated in specific cancer types. However, mutational analysis …